-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

532 Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Program: Oral and Poster Abstracts
Type: Oral
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management I
Hematology Disease Topics & Pathways:
Biological, Antibody Therapy, Cytokine Release Syndrome, Adults, Lymphomas, Non-Hodgkin Lymphoma, Non-Biological, Neurotoxicity, Clinical Research, B Cell Lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Diseases, Real World Evidence, Aggressive Lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, Study Population, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Sunday, December 12, 2021: 5:15 PM

Imran Nizamuddin, MD1, Kevin A. David, MD 2, Jonathon B. Cohen, MD, MS3, Vaishalee P. Kenkre, MD4, Geoffrey Shouse, PhD5,6, Brian T. Hess, MD7, Thomas A. Ollila, MD8, Deborah M. Stephens9, Sayan Mullick Chowdhury, DO, PhD10*, Robert Ferdman, MD11*, Kaitlyn O'Shea, PhD1*, Jieqi Liu, MD12, Jason T. Romancik, MD13, Joanna C. Zurko, MD14, Rahul S. Bhansali, MD15, Elyse I. Harris, MD16, McKenzie Sorrell, DO7, Rebecca Masel, MD17, Lindsey Fitzgerald, MD9, Carlos Galvez, MD1, Shuo Ma, MD18, Jane N. Winter, MD19, Barbara Pro, MD19, Leo I. Gordon, MD19, Alexey V. Danilov, MD, PhD20, Nirav N. Shah, MD21, Stefan K. Barta, MD, MRCP, MS15, Narendranath Epperla, MD, MS22, Pallawi Torka, MD23* and Reem Karmali, MD, MSc24

1Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
2Cancer Institute of New Jersey, New Brunswick, NJ
3Department of Hematology and Medical Oncology, Emory University, Atlanta, GA
4Carbone Cancer Center, University of Wisconsin, Madison, WI
5Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
6Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
7Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
8Lifespan Cancer Institute, Brown University, Providence, RI
9Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
10Ohio State University Medical Center, Columbus, OH
11Roswell Park Comprehensive Cancer Center, Buffalo, NY
12Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ
13Emory University Winship Cancer Institute, Atlanta, GA
14Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
15Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
16Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI
17Brown Alpert School of Medicine, Providence, RI
18Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
19Division of Hematology and Oncology, Northwestern University, Chicago, IL
20City of Hope Toni Stephenson Lymphoma Center, Duarte, CA
21Medical College of Wisconsin, Milwaukee, WI
22The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA, Columbus, OH
23Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
24Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL


The treatment of aggressive B-cell NHL has evolved rapidly over the last 5 years, owing to the FDA approval of 3 CD19 CAR T-cell constructs (CARTs) along with other novel targeted therapies. Real world practice data suggest that CARTs have been successfully administered in populations typically excluded from clinical trials. However, data on how to best utilize novel targeted agents as a pathway to CARTs and feasibility of CARTs in rare histologies remains limited. This retrospective multicenter study describes patient (pt) selection and practice patterns in pts treated with CD19 CARTs and provides insight on feasibility of CARTs in special populations.


Adult pts with R/R aggressive B-cell NHL treated with CD19 CARTs between 2015- 2020 across 12 US academic centers were identified. Data on demographic and clinical characteristics, disease and toxicity outcomes were collected. Univariate analyses (UVA) were performed to determine impact of demographic/clinical variables on survival. Survival curves were calculated using Kaplan-Meier method. Subgroup analysis was performed for pts with secondary central nervous system lymphoma (sCNSL).


Clinical and demographic features were recorded from 400 pts (Table 1). Median age was 59 years (range 18-84). Of 271 pts with immunohistochemistry data, 79 (29%) had double-expressor lymphoma. Of 178 pts with FISH data captured, 62 (35%) had double/triple-hit lymphoma. Most common histological subtypes included 271 (68%) pts with de novo DLBCL, 81 (20%) with transformed FL, 13 (3%) with Richter’s syndrome, and 8 (2%) with PMBCL. Rare histologies included 7 (2%) with transformed MZL, 5 (1%) with PTLD and 2 (0.5%) with grey zone lymphoma. 24 (6%) pts had sCNSL at time of CART apheresis. Two (0.5%) pts were HIV-positive.

Median number of lines of therapy prior to CART was 2 (range 1-8); 182 (46%) pts received ≥ 3 lines. 114 (28%) pts previously had an autologous stem cell transplant. Targeted therapies used as salvage regimens at any point prior to CART are listed in Table 2: commonly used salvage targeted therapies included lenalidomide based therapy (imids, n=37, 9%), BTK inhibitors (BTKis, n=30, 8%), checkpoint inhibitors (CBIs, n=17, 4%) and polatuzumab-containing regimens (n=10, 3%). 2 (1%) pts received loncastuximab, and no pts received tafasitamab.

Six (1.5%) pts proceeded to CART despite complete response to most recent pre-CART therapy. 191 (48%) pts received bridging between apheresis and CART infusion, choice of bridging noted in Table 2: the majority received chemotherapy (n=103, 54%); 28 (15%) received radiation (XRT); 25 (13%), 24 (13%) and 18 (9%) pts received imids, polatuzumab-containing regimens, or BTKis, respectively.

With median follow-up of 22.4 months (mo) for the overall group, median (m) PFS was 11 mo (n=363); mOS, was 27 mo (n=397; Fig 1). Pts with sCNSL had a mPFS and mOS of 2 and 4 mo, respectively (Fig 1). On UVA, factors predicting poorer PFS and OS in the overall group included 3 pre-CART lines (p </= 0.004), use of bridging (p </=0.001), IPI 4-5 at apheresis (p=0.014), LDH elevation at apheresis (p=/<0.001), and sCNSL (p </= 0.013).

For outcomes according to bridging regimens: mPFS after CART for most commonly used systemic bridging therapies was 86 days (d) for platinum-based chemotherapy, 77 d for imids, 90 d for BTKis, 98 d for polatuzumab-bendamustine/rituximab, and 274 d for XRT. Median PFS for XRT bridging (274 d) was statistically better when compared to mPFS for listed systemic therapies combined (p <0.05) (Fig 2).


Survival outcomes with CARTs in our data set are consistent with those reported in clinical trial settings. CARTs are utilized in real world practice in rare subsets of aggressive R/R B-cell NHL not routinely included in clinical trials. Despite early data suggesting pts with sCNSL benefit from CART, our data suggest outcomes with CART are dismal in this group. Targeted therapies including imids, polatuzumab, BTKis and CBIs are feasible choices for salvage and/or bridging as a pathway to CARTs. Bridging with XRT resulted in improved mPFS post CART as compared to bridging with systemic therapies and suggests differences in pt selection for each with systemic therapies likely favored in those with more widespread disease burden. Minimal use of CD19-targeted agents pre-CART is attributed to later approval of these agents and concern for potential loss of CD19 antigen leading to CART resistance.

Disclosures: Cohen: Janssen, Adicet, Astra Zeneca, Genentech, Aptitude Health, Cellectar, Kite/Gilead, Loxo, BeiGene, Adaptive: Consultancy; Genentech, BMS/Celgene, LAM, BioINvent, LOXO, Astra Zeneca, Novartis, M2Gen, Takeda: Research Funding. Shouse: Kite Pharma: Speakers Bureau; Beigene: Honoraria. Hess: ADC Therapeutics: Consultancy; BMS: Speakers Bureau. Stephens: CSL Behring: Consultancy; Adaptive: Membership on an entity's Board of Directors or advisory committees; Arqule: Research Funding; Mingsight: Research Funding; JUNO: Research Funding; Novartis: Research Funding; Abbvie: Consultancy; AstraZeneca: Consultancy; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Innate Pharma: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Epizyme: Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy. Ma: Pharmacyclics: Research Funding, Speakers Bureau; TG Therapeutics: Research Funding; Janssen: Research Funding, Speakers Bureau; Abbvie: Honoraria, Research Funding; Beigene: Research Funding, Speakers Bureau; Juno: Research Funding; AstraZeneca: Honoraria, Research Funding, Speakers Bureau; Loxo: Research Funding. Winter: BMS: Other: Husband: Data and Safety Monitoring Board; Actinium Pharma: Consultancy; Gilead: Other: Husband: Consultancy; Agios: Other: Husband: Consultancy; Epizyme: Other: Husband: Data and Safety Monitoring Board; Janssen: Other: Husband: Consultancy; Novartis: Other: Husband: Consultancy, Data and Safety Monitoring Board; Ariad/Takeda: Other: Husband: Data and Safety Monitoring Board; Merck: Consultancy, Honoraria, Research Funding; Karyopharm (Curio Science): Honoraria. Gordon: Zylem Biosciences: Patents & Royalties: Patents, No royalties; Bristol Myers Squibb: Honoraria, Research Funding. Danilov: Astra Zeneca: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Takeda Oncology: Research Funding; TG Therapeutics: Consultancy, Research Funding; Abbvie: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria; Gilead Sciences: Research Funding; Bristol-Meyers-Squibb: Honoraria, Research Funding; Rigel Pharm: Honoraria; Bayer Oncology: Consultancy, Honoraria, Research Funding; SecuraBio: Research Funding. Shah: Umoja: Consultancy; Legend: Consultancy; Kite: Consultancy; Miltenyi Biotec: Consultancy, Honoraria, Research Funding; Lily: Consultancy, Honoraria, Research Funding; Epizyme: Consultancy; Incyte: Consultancy. Barta: Seagen: Honoraria; Daiichi Sankyo: Honoraria; Acrotech: Honoraria; Kyowa Kirin: Honoraria. Epperla: Verastem: Speakers Bureau; Beigene: Speakers Bureau; Karyopharm: Other: Ad Board; Genzyme: Honoraria. Torka: TG Therapeutics: Membership on an entity's Board of Directors or advisory committees. Karmali: Morphosys: Consultancy, Speakers Bureau; Kite, a Gilead Company: Consultancy, Research Funding, Speakers Bureau; Karyopharm: Consultancy; Takeda: Research Funding; Epizyme: Consultancy; AstraZeneca: Speakers Bureau; Janssen/Pharmacyclics: Consultancy; EUSA: Consultancy; BeiGene: Consultancy, Speakers Bureau; BMS/Celgene/Juno: Consultancy, Research Funding; Genentech: Consultancy; Roche: Consultancy.

*signifies non-member of ASH